The subsequent accumulation of mutations can then become resistant to chemotherapy-induced apoptosis.10 Studies published after the Seal et al article (2006) have associated BRIP1 mutations with a higher risk of ovarian cancer than breast cancer.11-13 Patients with breast cancer are still tested for BRIP1 mutations but with a very low suspicion of a positive result. This evidence concerns the gene BRIP1 and breast cancer.